Drug Profile


Alternative Names: ABT 431; DAS-431

Latest Information Update: 30 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; DrugAbuse Sciences
  • Class Antiparkinsonians
  • Mechanism of Action Dopamine D1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cocaine abuse; Cognition disorders; Parkinson's disease

Most Recent Events

  • 26 Apr 2001 Discontinued-II for Parkinson's disease in Europe (Unknown route)
  • 26 Apr 2001 Discontinued-II for Parkinson's disease in USA (Unknown route)
  • 01 Mar 2001 A study has been added to the adverse events and therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top